Ultragenyx Pharma (RARE) Tops Q4 EPS by 1c

Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($0.52), $0.01 better than the analyst estimate of ($0.53).

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Trump discloses over $1.4 billion in crypto income in 2025 filing
• Columbus McKinnon names John Linker as CFO, reaffirms FY2027 guidance
• Baird starts Abbott at Outperform, sees product pipeline driving growth